Evidence map›Paper›PMID 34383195›Full record

ArticleImmunologic research2021

Serum decoy receptor 3 (DcR3): a promising biomarker for atopic asthma in children.

Asmaa Kamal, Azza K Abdelmegeid, Maha A M Gabr, Christine W S Basanti

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Asmaa KamalDepartment of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt. asmaakamal@kasralainy.edu.eg.ORCID http://orcid.org/0000-0002-2055-9843
Azza K AbdelmegeidDepartment of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt.
Maha A M GabrDepartment of Pediatrics, Kafr El Sheikh General Hospital, Kafr El Sheikh, Egypt.
Christine W S BasantiDepartment of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bronchial asthma is a common chronic inflammatory disease with high prevalence and morbidity, particularly in school-aged children. Decoy receptor 3 (DcR3) is a soluble decoy receptor that belongs to the tumor necrosis factor receptor superfamily and has been reported to be elevated in several allergic and inflammatory diseases. This study was designed to determine the role of DcR3 in pediatric asthma. The serum DcR3 levels were analyzed in 85 subjects (60 pediatric patients with bronchial asthma and 25 age- and sex-matched healthy control children) using the enzyme-linked immunosorbent assay technique. Patients with asthma had higher serum DcR3 levels than healthy control subjects (p = 0.007). In the atopic group of patients with asthma, the serum DcR3 levels were inversely correlated with the asthma control test score (R =  - 0.392, p = 0.039). Overall, DcR3 could be a promising biomarker of atopic asthma, specifically in pediatric patients.

Indexed as

AsthmaBiomarkersChildEnzyme-Linked Immunosorbent AssayFemaleHumansMaleReceptors, Tumor Necrosis Factor, Member 6bBiomarkersReceptors, Tumor Necrosis Factor, Member 6bTNFRSF6B protein, humanBiomarkerBronchial asthmaDcR3Inflammatory diseasesTNFRS

Identifiers

PMID34383195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.